Pembrolizumab in advanced renal cell carcinoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-000589-47

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

1. To estimate the objective response rate (ORR) per RECIST 1.1 as assessed by BICR in subjects with clear cell RCC. 2. To estimate the ORR per RECIST 1.1 as assessed by BICR in subjects with non-clear cell RCC.


Critère d'inclusion

  • Renal cell carcinoma (clear cell & non-clear cell), or kidney cancer